Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds.
Chumanevich AA, Chaparala A, Witalison EE, Tashkandi H, Hofseth AB, Lane C, Pena E, Liu P, Pittman DL, Nagarkatti P, Nagarkatti M, Hofseth LJ, Chumanevich AA.
Oncotarget. 2017 Jan 3;8(1):228-237. doi: 10.18632/oncotarget.13894.
Similar articles
Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties.
Chumanevich AA, Witalison EE, Chaparala A, Chumanevich A, Nagarkatti P, Nagarkatti M, Hofseth LJ.
Oncotarget. 2016 Aug 16;7(33):52928-52939. doi: 10.18632/oncotarget.10608.
Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer.
Witalison EE, Cui X, Causey CP, Thompson PR, Hofseth LJ.
Oncotarget. 2015 Nov 3;6(34):36053-62. doi: 10.18632/oncotarget.5937.
Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation.
Witalison EE, Thompson PR, Hofseth LJ.
Curr Drug Targets. 2015;16(7):700-10. Review.
Inhibiting protein arginine deiminases has antioxidant consequences.
Witalison EE, Cui X, Hofseth AB, Subramanian V, Causey CP, Thompson PR, Hofseth LJ.
J Pharmacol Exp Ther. 2015 Apr;353(1):64-70. doi: 10.1124/jpet.115.222745. Epub 2015 Jan 29.
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest.
Cui X, Witalison EE, Chumanevich AP, Chumanevich AA, Poudyal D, Subramanian V, Schetter AJ, Harris CC, Thompson PR, Hofseth LJ.
PLoS One. 2013;8(1):e53791. doi: 10.1371/journal.pone.0053791. Epub 2013 Jan 7.
Filters: Manage Filters